Cardiovascular Genetic Testing Market Report 2026

The cardiovascular genetic testing market size has grown rapidly in recent years. It will grow from $3.93 billion in 2025 to $4.35 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to increasing awareness of inherited cardiovascular disorders, expansion of molecular diagnostic capabilities, declining costs of genetic sequencing, growing use of genetic counseling services, increased research in cardiovascular genomics.

The cardiovascular genetic testing market size is expected to see rapid growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to increasing demand for precision medicine approaches, rising adoption of population-based genetic screening, expansion of AI-driven variant interpretation, growing integration of genomics in clinical decision making, increasing focus on preventive cardiovascular healthcare. Major trends in the forecast period include increasing adoption of predictive genetic risk assessment, rising use of multigene panel testing, growing integration of bioinformatics and AI analytics, expansion of pharmacogenomic testing applications, enhanced focus on personalized cardiovascular care.

The rising prevalence of cardiovascular diseases is projected to support the growth of the cardiovascular genetic testing market in the coming years. Cardiovascular diseases (CVDs) include a range of disorders affecting the heart and blood vessels, such as heart attacks, strokes, and hypertension. The prevalence of cardiovascular diseases is increasing largely due to sedentary lifestyles linked to urbanization, which contribute to obesity, high blood pressure, and metabolic conditions. The growing incidence of cardiovascular diseases increases demand for cardiovascular genetic testing, as early identification of genetic risks enables personalized prevention strategies and targeted treatments to reduce the risk of severe heart complications. For example, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, representing a 4% increase from 224.4 per 100,000 in 2023. Therefore, the rising prevalence of cardiovascular diseases is contributing to the growth of the cardiovascular genetic testing market.

Leading companies operating in the cardiovascular genetic testing market are concentrating on developing innovative solutions, such as clinician-ordered tests, to ensure medical necessity and customization based on patient-specific conditions, reducing unnecessary testing and associated costs. A clinician-ordered test is a diagnostic procedure requested by a healthcare professional to assess, monitor, or guide the management of a patient’s health condition. For instance, in September 2025, Mass General Brigham, a US-based not-for-profit integrated academic healthcare system, in partnership with Broad Clinical Labs and the Mass General Brigham Laboratory for Molecular Medicine, launched a genetic test evaluating inherited risk for eight cardiovascular conditions. The clinician-ordered test is offered on a self-pay basis and assesses genetic predisposition to conditions such as atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Its development utilized genotype and clinical data from 236,393 participants in the NIH’s All of Us Research Program. Publicly available polygenic risk scores were integrated using PRSmix, an elastic-net modeling approach combining multiple component scores into a single comprehensive risk score per disease. High-resolution genetic data is captured through a blended genome-exome assay at Broad Clinical Labs, while the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine interprets results and generates patient-friendly reports.

In February 2025, Tempus AI Inc., a US-based precision medicine company, acquired Ambry Genetics for an undisclosed amount. This acquisition strengthens Tempus AI’s strategy of combining diagnostics and data-driven insights to fuel innovation, enhancing its ability to deliver advanced solutions to healthcare providers, patients, and life sciences organizations. Ambry Genetics Corporation is a US-based company focused on cardiovascular genetic testing services.

Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.

Tariffs are impacting the cardiovascular genetic testing market by increasing costs of imported sequencing instruments, reagents, bioinformatics hardware, and advanced laboratory equipment. Diagnostic laboratories and research institutions in North America and Europe are most affected due to reliance on imported genomic technologies, while Asia-Pacific faces higher costs for test kit manufacturing and distribution. These tariffs are increasing testing expenses and slowing laboratory expansion. However, they are also encouraging domestic reagent production, localized sequencing infrastructure, and regional bioinformatics platform development that strengthen long-term testing capacity.

The cardiovascular genetic testing market research report is one of a series of new reports that provides cardiovascular genetic testing market statistics, including cardiovascular genetic testing industry global market size, regional shares, competitors with a cardiovascular genetic testing market share, detailed cardiovascular genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular genetic testing industry. This cardiovascular genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cardiovascular genetic testing involves examining an individual’s DNA to detect inherited genetic variants that elevate the likelihood of developing diseases of the heart and blood vessels, supporting early identification, individualized treatment decisions, and focused preventive measures. It allows healthcare professionals to estimate disease risk, inform medication choices, evaluate hereditary predisposition, and facilitate proactive cardiovascular care through precision-based medical strategies.

The primary testing types of cardiovascular genetic testing include predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and other testing categories. Predictive testing consists of genetic assessments that evaluate an individual’s likelihood of developing cardiovascular disorders prior to symptom onset. These tests are applied to diseases such as inherited cardiomyopathies, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmias, aortopathies, and other related conditions. The technologies involved include cytogenetic testing, biochemical testing, and molecular testing. The applications cover chromosome analysis, genetic disease identification, cardiovascular disease diagnosis, and other uses, while the end users include hospitals and clinics, diagnostic laboratories, research organizations, genetic counseling centers, pharmaceutical companies, and direct-to-consumer testing providers.

The cardiovascular genetic testing market includes revenues earned by entities through genetic testing services, genetic screening services, molecular diagnostic services, genomic sequencing services, variant interpretation services, bioinformatics analysis services, genetic counseling services, and personalized risk assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.